MannKind Corporation (NASDAQ:MNKD) announced that its inhaled insulin drug, Afrezza, generated $1.1 million in sales in France. Unfortunately, it is the distributor, Sanofi, who gets to make the most of it. Analysts had hoped that the drug would make $3-$4 million in sales. The stock of the company has been…